What steps did scientists take to learn the basics about ERBB activation? EGFR has been the most extensively studied with respect to activation compared with the other ERBB receptors, so our ...
Epidermal growth factor receptor (EGFR) is a major driver of cancer dissemination and target for anti-cancer therapies but ...
However, activation of the Ras–MAPK pathway has not been as well correlated with response to EGFR inhibitors as the PI3K–Akt pathway 158. Experience with gefitinib and erlotinib has taught us ...
EU regulators have issued a positive opinion for the extension of the market authorization for subcutaneous formulation of ...
EMA committee recommends extension of marketing authorisation for Janssen-Cilag’s subcutaneous Rybrevant to treat advanced EGFR-mutated NSCLC: Beerse, Belgium Tuesday, February ...
The Committee for Medicinal Products for Human Use (CHMP) has recommended that the subcutaneous (SC) formulation be approved ...
Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended an ...
The committee recommended the new formulation in two EGFR-mutated advanced NSCLC settings, for which intravenous Rybrevant is already available.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback